Objective: To determine whether the combined intervention of 50 000 IU vitamin A administered together with Bacille Calmette-Guerin (BCG) vaccination at birth was associated with adverse events, in particular bulging fontanels and adverse reactions to BCG. Subjects/Methods: From an ongoing trial, 2145 infants randomized to 50 000 IU vitamin A or placebo with BCG vaccination were recruited. Adverse events were monitored in two different ways: (A) daily clinical examinations by a medical doctor during the first 3 days post supplementation; (B) weekly interviews by a trained assistant during the first month post supplementation. Results: In part A, 1271 infants were enrolled, in part B 2078. Vitamin A supplementation (VAS) was associated with a relative risk (RR) of bulging fontanels of 1.16 (95% confidence interval (CI) ¼ 0.82-1.65). The rate of health care contacts and various symptoms during the first month were comparable between the groups. VAS was associated with larger peak local reactions to BCG vaccination in boys, but not in girls (P-value for test of interaction between VAS and sex ¼ 0.02). Conclusion: 50 000 IU vitamin A with BCG was not associated with adverse events. The observed sex-differential effect of VAS on local reaction to BCG is in line with other observations of sex-differential effects of VAS.
Introduction
Two Asian studies reported vitamin A supplementation (VAS) at birth to be associated with decreased mortality (Humphrey et al., 1996; Rahmathullah et al., 2003) . Recently, a study in an African population reported no overall effect of VAS at birth in infants of HIV-negative mothers (Malaba et al., 2005) and a possible-negative effect in uninfected children of HIV-positive mothers (Humphrey et al., 2006) . None of the above studies reported whether VAS was given with other interventions. We have previously hypothesized that the effect of VAS may depend on amplification of nonspecific effect of vaccines, being more beneficial when administered with live vaccines such as Bacille CalmetteGuerin (BCG) or measles (Benn et al., 2003) . World Health Organization (WHO) recommends BCG vaccine at first health contact, preferably at birth. To explore the potential benefits of VAS given with BCG vaccination at birth in a high-mortality African setting, we conducted a large randomized double-blind placebo-controlled trial in Guinea-Bissau from 2002 to 2005. Normal birth-weight infants who were to receive BCG vaccination were randomized to 50 000 IU vitamin A or placebo. In a subgroup of participants, we conducted a study of possible adverse events associated with this combined intervention.
High-dose vitamin A can transiently increase intracranial volume (ICV), leading to increased intracranial pressure (ICP) (Olson, 1994) . Several studies from Bangladesh, which administered VAS to 1-6-month-old infants with each of the three DTP vaccinations (25 000 or 50 000 IU, reaching a total of 75 000-150 000 IU), reported increased incidence of transient fontanel bulging in the supplemented group (de Francisco et al., 1993; Baqui et al., 1995; Rahman et al., 1995; Mahalanabis et al., 1997) . In one of the studies, a positive association between bulging and symptoms of raised ICP was noted (Baqui et al., 1995) ; however, this was not the case in other studies. The results have also been conflicting with regard to VAS administered at birth. The first safety study of 50 000 IU VAS at birth, performed in Indonesia, reported an increased incidence of fontanel bulging among VAS recipients. The VAS and placebo groups did not differ with regard to any other sign or symptom assessed (Agoestina et al., 1994) . Increased bulging was not found in the two other studies of neonatal supplementation from India (Rahmathullah et al., 2003) and Zimbabwe (Iliff et al., 1999) , but the Indian study only registered adverse events after a first dose of 24 000 IU VAS. In the present study, we aimed to study the possible adverse events after 50 000 IU VAS administered with BCG vaccination in a high-mortality African setting. We particularly aimed to assess the risk of bulging fontanels and adverse reactions to BCG vaccine.
Methods

Study design
The Bandim Health Project runs a demographic surveillance system in six suburban districts of Bissau, Guinea-Bissau. The present study was done in a subcohort of children included in a randomized study of vitamin A vs placebo. The enrolment in the randomized study has been described in detail elsewhere (Benn et al., 2007) . In brief, all infants from the study area born at the main hospital in Bissau or reporting for BCG vaccination at two out of three health centres in the study area were screened for enrolment. Mothers were invited to participate if the infant weighed X2500 g and had no overt illness. All children were vaccinated intradermally in the upper left deltoid region with 0.05 ml BCG (Statens Serum Institut, Copenhagen, Denmark). If she accepted to participate in the study, the mother had to draw a lot from an envelope determining whether the child should receive VAS or placebo. The envelopes were prepared by the study supervisor. Each contained 100 lots, 50 marked '1' and 50 marked '2', indicating from which of the two numbered bottles, '1' or '2', the child should receive its supplement. A total of 4345 infants were randomized to receive oral vitamin A (50 000 IU retinol palmitate in vegetable oil, with 20 IU vitamin E as antioxidant) or placebo (the same amount of vegetable oil and vitamin E). Vitamin A and placebo were prepared at Skanderborg Pharmacy, Skanderborg, Denmark. Apart from the randomization number, the bottles looked alike. A total of 112 mothers were asked whether they believed their child had received vitamin A or placebo. There were no differences in answers from mothers of VAS or placebo recipients. None of the three assistants who were responsible for the randomization procedures at the hospital and at the health centres had any idea about which bottles contained vitamin A or placebo. The code was kept at the pharmacy until 12 months after the last child was enrolled. At enrolment, information on baseline anthropometrics and socioeconomic characteristics was collected.
We aimed to enrol 800 children from the randomized study into the study of adverse events, to reach a sample size comparable to the previous African study of adverse events after 50 000 IU vitamin A at birth (Iliff et al., 1999) . As the data collection proceeded well, we did not stop the inclusion of children in the adverse event study until more children had been recruited. The adverse event study consisted of two parts: daily visits on days 1-3 by a medical doctor (Part A) and weekly visits on the first 4 weeks by a trained field assistant (Part B). The medical doctor and the field assistant were unaware of treatment allocation. Eligibility criteria were enrolment in the randomized study and home address in one of the four districts closest to the office of the health project. If the doctor was travelling or absent, no inclusions were made for Part A of the study, as described in Figure 1 . For logistic reasons, a maximum of 35 children per week were enrolled into Part B.
Registration of symptoms Part A. On the medical doctor's daily visits, information about morbidity was collected and the infant was examined. To judge irritability of the infant, the mother was asked how much the child cried compared with other newborns: 'less than normal', 'normally' or 'more than normal'. The temperature was measured in the axilla using an electronic thermometer recording one decimal. Fever was defined as axillary temperature equal to or above 37.51C. Respiratory frequency was counted over 1 min while the child relaxed. The fontanels were examined when the child was calm and in an upright position, and characterized as 'very depressed', 'slightly depressed', 'normal', 'slightly bulging' or 'very bulging'. A study from Indonesia found good inter-observer correlation of judgement of bulging fontanel and a weak association between this outcome and the resistive index in Figure 1 Time line of adverse event study.
Effects of vitamin A and BCG on newborns JE Nante et al the anterior cerebral artery as evaluated by duplex Doppler (Agoestina et al., 1994) .
Part B. The visits were conducted on approximately days 7, 14, 21 and 28 after inclusion. The trained field worker systematically interviewed the mother/caretaker of the child about symptoms and health care contacts since the last visit. The injection site of the BCG vaccine was examined. Any local reaction was measured horizontally and vertically to nearest millimetre with a transparent ruler. The mean of the horizontal and vertical diameter was used in the analysis of size of reaction. For each child, the largest size of reaction observed at any of the home visits was considered the peak local reaction to the vaccine.
Deaths were registered in visits from part A or B deaths and detected by the routine surveillance system. Cause of death was investigated by verbal autopsy.
Statistical analysis
Risks of adverse effects were compared for the vitamin A and the placebo groups during the first 3 days and the first 4 weeks post supplementation. A symptom was defined as present if noted at any one visit, irrespective of whether all visits were conducted. A symptom was defined as absent if the symptom was not recorded at any visit.
We calculated relative risks (RRs) separately for each sex as the previous two studies conducted in India and Indonesian indicated that there might be differential effects of VAS in boys and girls (Benn et al., 2006) . We have presented separate results where relevant, otherwise the results were adjusted for sex by Mantel-Haenszel stratification. Continuous variables were compared using Student's t-test. For explorative analyses of interactions, linear regression analysis was performed.
In order not to overlook any adverse events in potentially vulnerable subgroups, we examined three groups: (I) highest quartile of weight-at-inclusion, presumably having had the highest retinol level before supplementation, (II) lowest quartile of weight-at-inclusion, representing the group receiving the highest per kg dose of vitamin A, and (III) children included during the rainy season, because our mortality data demonstrated a less favourable effect of supplementation in this group. Again, analyses were performed both for each sex separately and together. To gain power, one or more of the following symptoms was categorized as 'serious event': (1) very bulging fontanel, (2) bulging fontanel with simultaneous irritability or vomiting, (3) local reactions to BCG vaccine 410 mm in diameter or requiring incision or antibiotics, (4) illness leading to medical contact, (5) hospitalization, and (6) death.
Significance was defined as P-valueo0.05. Statistical analysis was conducted with the use of Stata 9.2 (StataCorp, TX, USA).
Ethical considerations
The protocol was presented to The Ministry of Health in Guinea-Bissau and to the Danish Central Ethical Committee for approval (2004-7041-19) . The study was registered under clinicaltrials.gov, number NCT00168598. The sponsors had no role in the study design, data collection, data analysis, data interpretation or the writing of the report.
Results
In part A, 1271 children were enrolled, in part B 2078. Because 1204 children participated in both parts, this led to a total of 2145 individual children being enrolled. The children enrolled represented 49% of the children included in the main study (Figure 2) , and 95% of eligible children. The remaining eligible children (n ¼ 109) were not included for logistic reasons and/or because they did not have a valid address at the time.
There was no difference between the vitamin A and placebo groups in terms of baseline characteristics (Table 1) .
Risk of adverse events during the first 3 days post supplementation
Of 1271 infants enrolled in part A (624 from the VAS group, 647 from the placebo group), 1150 (90%) were met at least once. Mean number of successful visits was 2.8 in both Effects of vitamin A and BCG on newborns JE Nante et al groups. We registered a lower risk of having passed more than five stools during the last 24 h in the vitamin A group (Table 2 ). There were no other significant differences between the two groups ( Table 2 ). The fontanels were found to be slightly bulging in 115 (10%) of the children (60 vitamin A, 55 placebo) and very bulging in 1 (0.1%) of the children (a boy from the placebo group). This child had not vomited, suggesting that he did not have increased intracranial pressure. The group of children with slightly bulging fontanel did not display increased frequency of symptoms that could indicate raised intracranial pressure (irritability or vomiting) as compared with children without bulging, nor did mothers of children with bulging fontanel consider their child to be more ill (data supplied at request). The RR for having slightly or very bulging fontanels between the VAS and placebo groups was 1.16 (0.82-1.65). There was no difference in effect of vitamin A with regard to any of the outcomes between boys and girls.
Risk of adverse events during the first month post supplementation Of 2078 infants enrolled (1068 VAS group, 1010 placebo group), 1955 were visited at least once. The mean number of visits in both groups was 3.7. The results are presented in Table 3 . We observed no differences in any of the measured outcomes.
Reaction to BCG vaccination
Overall 50.5% of the children developed a measurable reaction to BCG vaccination during the 4 weeks after its administration. There was no difference in the percentage of children having a local reaction to the vaccine in the two groups. One child, a boy in the vitamin A group, had a very large local reaction (63*50 mm). The child was not described as sick or febrile by the mother. He died shortly before 2 months of age, presumably from an acute pneumonia (data from verbal autopsy). We have no information about his HIV status. This reaction was considered outside the normal range and was excluded from all analyses of local reactions. Results are presented in Table 4 . Boys in the vitamin A group had significantly larger peak local reactions to BCG vaccination than their peers receiving placebo (P ¼ 0.01), and the interaction between sex and randomization group was significant (P ¼ 0.02).
Potentially vulnerable subgroups
In the potentially vulnerable subgroups, VAS was not associated with increased risk of serious events, the overall frequency of events defined as serious was 14.8%, with an RR between the VAS and the placebo group of 1.01 (0.82-1.25). The figures were comparable within each of the three vulnerable subgroups and between the two sexes (data not shown).
Mortality
Seventeen children (nine VAS, eight placebo) of the 4345 participants in the randomized study died within the first 3 days after supplementation, (RR ¼ 1.16 (0.45-2.98)). A further 25 infants (13 VAS, 12 placebo) died within the first 28 days after supplementation, leading to an RR of death within the first 28 days following supplementation of 1.14 (0.62-2.07). Asphyxia/sepsis was the most frequent cause, accounting for 25 fatalities (15 VAS, 10 placebo). Six deaths were due to haemorrhage (two VAS, four placebo); other causes were respiratory infection (three from the placebo group) and bowel obstruction (one from the placebo group). In seven deaths (five VAS, two placebo), the cause was not established. Effect of VAS did not vary significantly by sex; the causes of death were similar in boys and girls.
Discussion
No serious adverse events or side effects were detected to be more common in the vitamin A group in the present study. Only one case of very bulging fontanel was observed, and it was in the placebo group. Potentially VAS affects the local reaction to BCG vaccination in boys but the significance of this finding is uncertain. The children enrolled in the adverse event study constitute 49% of the children included in the main randomized study. For practical reasons, we did not enrol children living in the district farthest away from the health project and we stopped inclusion while enrolment for the main study was still ongoing. We do not believe that this selection has introduced bias. However, the eligible children not enrolled because of lack of known address at the time of enrolment are likely to represent a group with more migration than the enrolled children. Fortunately, most of these children were later identified, and mortality in the group was comparable to mortality in the studied group. If tolerance of vitamin A was different among migrating children, we could have failed to detect it. However, that seems unlikely. High-dose vitamin A is associated with increased intracranial volume (Olson, 1994) . In Indonesia, VAS at birth was associated with a significant increase in episodes of bulging fontanel within the first 24 h after birth; 50 000 IU VAS increased the percentage significantly by 1.9-4.6%. Some of the infants with bulging fontanel were subjected to duplex Doppler cranial sonography; bulging fontanels were not associated with increased ICP, probably due to the accommodation of the infant cranium (Agoestina et al., 1994) . A follow-up study at 3 years of age found no long-term effect of bulging on growth and development (Humphrey et al., 1998) . Thus, VAS may induce fontanel bulging, but this bulging appears to be without short-or long-term neurological consequences.
In our study, the prevalence of bulging fontanel was much higher (10.9 and 9.4% in the VAS and placebo groups, respectively) than in the Indonesian (4.6 and 2.7%) (Agoestina et al., 1994) and the Zimbabwean study (1.5 and 1.0%) (Iliff et al., 1999) . The Indian study reported no cases among 11 619 infants 24 h after 24 000 IU (Rahmathullah et al., 2003) . However, we only found one case of very bulging fontanel in the placebo group, the rest being only slightly bulging. We did not find VAS to be associated with bulging fontanels. In our study, as in most others, there was no association between symptoms of raised ICP (irritability and vomiting) and bulging fontanel. Irrespectively, a bulging fontanel may be perceived by the mother as a negative consequence of VAS and could lead to decreased participation in VAS programmes. However, we found no indication that mothers of children with bulging fontanels perceived their children to be more irritable or less well.
We tested many different signs and symptoms and statistical significance in some of the comparisons was not unexpected, due to multiple testing. We found a significant difference between the vitamin A and placebo groups with regard to occurrence of five or more bowel movements during a 24 h period. This may be a chance finding; however, it should be noted that in the Indonesian adverse events study only four infants experienced three or more loose stools between 12 and 24 h post dosing, and all four were in the control group (Agoestina et al., 1994) .
We found no indication that vitamin A supplementation affected the overall frequency of adverse reactions to BCG vaccination when given simultaneously with BCG vaccination. We observed a significant increase in the peak size of the local reaction in the vitamin A group among boys, resulting in a significant interaction between sex and effect of supplementation. This finding is in line with previous findings from Guinea-Bissau. In a study of VAS with measles vaccine, we found VAS to be significantly associated with higher levels of measles-specific antibodies in boys, but not in girls (Benn et al., 1997) . Also, we found a smaller dose of VAS than the currently recommended to be beneficial in girls, but not in boys (Benn et al., 2005) . In the present study, boys who received VAS tended to survive better than boys who received placebo, whereas the opposite was seen in girls (Benn et al., 2007) . Thus, the currently available data suggest that boys may benefit more from VAS than girls. To our knowledge, no study has linked size of the local postvaccination reaction with long-term efficacy of BCG vaccine, but it seems possible that larger size could reflect a better immune stimulation.
Overall, the present study confirms the finding of previous studies, demonstrating that a 50 000 IU oral dose of vitamin A is well tolerated by young infants, also when given with BCG. Should simultaneous administration of BCG and vitamin A become policy, the combination can be expected to be safe in terms of side effects, although the increased local reaction to BCG in boys who received VAS merits further investigation.
